Physician profile
John Havill
NPI 1407097280
$3,594.12
in general payments reported to CMS, 2019-2025
28 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $72.38 · 2021: $66.70 · 2022: $329 · 2023: $605 · 2024: $924 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,552 · Education: $35.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.16 |
| Education | $35.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $895.15 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $304.27 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $299.91 | 2019-2025 | Jynarque |
| Amgen INC. | $260.85 | 2019-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $225.44 | 2019-2024 | Veltassa |
| Calliditas Therapeutics US INC. | $179.20 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.73 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $131.99 | 2019-2023 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $129.09 | 2022-2023 | Acthar |
| Novartis Pharmaceuticals Corporation | $127.50 | 2019-2025 | |
| Novo Nordisk INC | $110.44 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Aurinia Pharma U.S., INC. | $106.36 | 2022-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $98.00 | 2023-2024 | Benlysta, Jesduvroq |
| Akebia Therapeutics INC | $97.68 | 2025 | Vafseo |
| Travere Therapeutics, INC. | $94.71 | 2019-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $82.09 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $47.94 | 2019-2023 | Injectafer |
| Lilly USA, LLC | $45.69 | 2024 | Jardiance |
| Opko Pharmaceuticals, LLC | $35.64 | 2019-2022 | |
| Medtronic, INC. | $28.52 | 2025 | Symplicity G3 |
| Genzyme Corporation | $25.95 | 2019 | |
| Mallinckrodt Enterprises LLC | $21.54 | 2019 | |
| Fresenius USA Marketing, INC. | $21.28 | 2025 | Velphoro |
| Shield Therapeutics INC | $20.67 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.08 | 2019 | |
| Nxstage Medical, INC. | $16.99 | 2019 | |
| Apellis Pharmaceuticals, INC. | $16.47 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $14.94 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Havill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.